Nabriva Therapeutics plc

NasdaqCM:NBRV Stock Report

Mkt Cap: US$4.6m

Nabriva Therapeutics Past Performance

How has Nabriva Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


12.8%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: NBRV is currently unprofitable.

Growing Profit Margin: NBRV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: NBRV is unprofitable, but has reduced losses over the past 5 years at a rate of 12.8% per year.

Accelerating Growth: Unable to compare NBRV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NBRV is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).


Return on Equity

High ROE: NBRV has a negative Return on Equity (-185.26%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies